Global Human Papilloma Virus (HPV) Vaccine Market Size, Share, Opportunities, COVID 19 Impact, And Type (Quadrivalent HPV Vaccine, Bivalent HPV Vaccine), By Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Vulvar Cancer, Mouth Cancer, Genital Warts), By Gender (Male. Female), And By Geography - Forecasts From 2019 To 2024

Published:  Jan 2022 Report Code: KSI061611186 Pages: 130

The human papilloma virus (HPV) vaccine market is projected to witness a compound annual growth rate of 8.51% to grow to US$4,481.480 million by 2026, from US$2,529.765 million in 2019. According to the WHO guidelines, routine vaccination is recommended to all countries along with other vaccinations. Human Papilloma Virus (HPV) Vaccine protects from certain types of Human Papilloma Viruses that can lead to cancer or genital warts. According to the WHO guidelines, routine vaccination is recommended to all countries along with other vaccinations. These vaccines are on the “World Health Organisation’s list of Essential Medicines” and are considered safe and effective medicines.

The market for the global Human Papilloma Virus (HPV) Vaccine is augmented by the increasing number of Cervical Cancer cases worldwide. Rising awareness regarding cervical cancer and HPV owing to the number of initiatives by the governments will also boost the market for the HPV vaccines. However, a strict regulatory approval process for the vaccines might restrain the growth of the market during the given time frame.     

The Global Human Papilloma Virus (HPV) Vaccine Market – Forecasts from 2021 to 2026” is an exhaustive study that aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key markets, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by type, indication, gender, and geography.

Based on type, the market has been segmented as Quadrivalent HPV Vaccine and Bivalent HPV Vaccine. On the basis of indication, the market is divided into Cervical Cancer, Anal Cancer, Vaginal Cancer, Vulvar Cancer, Mouth Cancer, and Genital Warts. The market is divided into Girls and Boys on the basis of Gender.

Regional analysis has been provided with detailed analysis and forecast for the period 2019 to 2024. The global market has been broken down into North America, South America, Europe, the Middle East and Africa, and Asia Pacific regions. The report also analyzes major countries across these regions with thorough analysis and forecast along with prevailing market trends and opportunities which each of these countries present for the manufacturers.

Major players in the Human Papilloma Virus (HPV) Vaccine market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the Human Papilloma Virus (HPV) Vaccine market.

Global Human Papilloma Virus (HPV) Vaccine Market Scope:

Report Metric Details
 Market size value in 2018  US$3.305 billion
 Market size value in 2024  US$5.790 billion
 Growth Rate  CAGR of 9.79% from 2018 to 2024
 Base year  2018
 Forecast period  2019–2024
 Forecast Unit (Value)  USD Billion
 Segments covered  Type, Indication, Gender, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered  Merck & Co Inc., GlaxoSmithKline plc, Sanofi S.A., Janssen Pharmaceuticals, Inc.,   Inovio Pharmaceuticals Inc., Pfizer Inc., EyeGene Inc.
 Customization scope  Free report customization with purchase

Segmentation:

  • By Type
    • Quadrivalent HPV Vaccine
    • Bivalent HPV Vaccine
    • 9-Valent HPV Vaccine
  • By Indication
    • Cervical Cancer
    • Anal Cancer
    • Vaginal Cancer
    • Vulvar Cancer
    • Mouth Cancer
    • Genital Warts
  • By Gender
    • Male
    • Female
  • By Geography
    • North America
      • USA
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • Italy
      • Spain
      • Others
    • Middle East and Africa (MEA)
      • Israel
      • Saudi Arabia
      • Others
    • Asia Pacific (APAC)
      • China
      • Japan
      • India
      • Australia
      • Others

Frequently Asked Questions (FAQs)

Q1. What will be the human papilloma virus (HPV) vaccine market size by 2024?
A1. The global human papilloma virus (HPV) vaccine market is expected to reach a total market size of US$5.790 billion by 2024.

Q2. What is the size of global human papilloma virus vaccine market?
A2. Human Papilloma Virus (HPV) Vaccine market was valued at US$3.305 billion in 2018.

Q3. What are the growth prospects for human papilloma virus vaccine market?
A3. The human papilloma virus vaccine market is expected to grow at a CAGR of 9.79% during the forecast period.

Q4. How is the global human papillomavirus (HPV) vaccine market segmented?
A4. The global human papilloma virus (HPV) vaccine market has been segmented by type, indication, gender, and geography.

Q5. What factors are anticipated to drive the human papillomavirus vaccine market growth?
A5. The market for global Human Papilloma Virus (HPV) Vaccine is augmented by increasing the number of Cervical Cancer cases worldwide.

1. INTRODUCTION

1.1. Market Overview

1.2. Covid-19 Scenario

1.3. Market Definition

1.3. Scope of the Study

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Secondary Sources

2.3. Validation

3. KEY FINDINGS

4. MARKET DYNAMICS

4.1. Segmentation

4.2. Drivers

4.2.1. Growing Cases of HPV Associated Cancers

4.2.2. Initiatives by Governments and Organizations

4.3. Restraints

             4.3.1. Strict Process for Regulatory Approval

4.4. Porter’s Five Forces Analysis

4.4.1. Bargaining Power of Suppliers

4.4.2. Bargaining Power of Buyers

4.4.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.4.5. Competitive Rivalry in the Industry

4.5. Industry Value Chain Analysis

5. HUMAN PAPILLOMA VIRUS VACCINE MARKET BY TYPE

5.1. Introduction

5.2. Quadrivalent HPV Vaccine

5.3. Bivalent HPV Vaccine

5.4. 9-Valent HPV Vaccine

6. HUMAN PAPILLOMA VIRUS VACCINE MARKET BY INDICATION

6.1. Introduction

6.2. Cervical Cancer

6.3. Anal Cancer

6.4. Vaginal Cancer

6.5. Vulvar Cancer

6.6. Mouth Cancer

6.7. Genital Warts

6.8. Others

7. HUMAN PAPILLOMA VIRUS VACCINE MARKET BY GENDER

7.1. Introduction

7.2. Male

7.3. Female

8. HUMAN PAPILLOMA VIRUS VACCINE MARKET BY GEOGRAPHY

8.1. North America

8.1.1. USA

8.1.2. Canada

8.1.3. Mexico

8.2. South America

8.2.1. Brazil

8.2.2. Argentina

8.2.3. Others

8.3. Europe

8.3.1. United Kingdom

8.3.2. Germany

8.3.3. Italy

8.3.4. Spain

8.3.5. Others

8.4. Middle East and Africa

8.4.1. Israel

8.4.2. Saudi Arabia

8.4.3. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. Japan

8.6.3. India

8.6.4. Australia

8.6.5. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Emerging Players and Market Lucrativeness

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

10.1. Merck & Co Inc.

10.1.1. Overview

10.1.2. Products and Services

10.1.3 Financials

10.1.4. Key Developments

10.2. GlaxoSmithKline Plc

10.2.1. Overview

10.2.2. Products and Services

10.2.3 Financials

10.3. Sanofi S.A.

10.3.1. Overview

10.3.2. Products and Services

10.3.3 Financials

10.3.4. Key Developments

10.4. Xiamen Innovax Biotech Co. Ltd. (Innovax)

10.4.1. Overview

10.4.2. Products and Services

10.4.3. Key Developments

10.5. Inovio Pharmaceuticals Inc.

10.5.1. Overview

10.5.2. Products and Services

10.5.3. Financials

10.5.4. Key Developments

10.6. Janssen Pharmaceuticals Inc

10.6.1. Overview

10.6.2. Products and Services

10.6.3. Key Developments

10.7. Serum Institute of India Pvt. Ltd.

10.7.1. Overview

10.7.2. Products and Services

LIST OF TABLES

LIST OF FIGURES

Merck & Co Inc.

GlaxoSmithKline plc

Sanofi S.A.

Janssen Pharmaceuticals, Inc.

Inovio Pharmaceuticals Inc.

Pfizer Inc.

EyeGene Inc.

 

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us